CBIO Long Call Strategy
CBIO (Crescent Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO (Crescent Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $610.3M, a beta of 1.22 versus the broader market, a 52-week range of 8.72-27.41, average daily share volume of 331K, a public-listing history dating back to 2014, approximately 44 full-time employees. These structural characteristics shape how CBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.22 places CBIO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on CBIO?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
CBIO snapshot
As of August 14, 2026, spot at $16.91, ATM IV 131.40%, IV rank 53.79%, expected move 37.67%. The long call on CBIO below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long call structure on CBIO specifically: CBIO IV at 131.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 37.67% (roughly $6.37 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on CBIO should anchor to the underlying notional of $16.91 per share and to the trader's directional view on CBIO stock.
CBIO long call setup
The CBIO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CBIO at $16.91 on that close, the first option leg uses a $16.91 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CBIO chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $16.91 | N/A |
CBIO long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
CBIO long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on CBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on CBIO
Long calls on CBIO express a bullish thesis with defined risk; traders use them ahead of CBIO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
CBIO thesis for this long call
The market-implied 1-standard-deviation range for CBIO extends from approximately $10.54 on the downside to $23.28 on the upside. A CBIO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current CBIO IV rank near 53.79% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on CBIO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, CBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CBIO-specific events.
CBIO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CBIO alongside the broader basket even when CBIO-specific fundamentals are unchanged. Long-premium structures like a long call on CBIO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current CBIO chain quotes before placing a trade.
Frequently asked questions
- What is a long call on CBIO?
- A long call on CBIO is the long call strategy applied to CBIO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With CBIO stock at $16.91 on the most recent close, the strikes shown on this page are snapped to the nearest listed CBIO chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are CBIO long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the CBIO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 131.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CBIO long call?
- The breakeven for the CBIO long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CBIO market-implied 1-standard-deviation expected move in the same options snapshot is approximately 37.67%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on CBIO?
- Long calls on CBIO express a bullish thesis with defined risk; traders use them ahead of CBIO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current CBIO implied volatility affect this long call?
- CBIO ATM IV is at 131.40% with IV rank near 53.79%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.